ClinicalTrials.gg
RecruitingNCT06831552RISE in HR NBLUpdated Nov 13, 2026

Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

An interventional study of RISE Intervention in Neuroblastoma and High-risk Neuroblastoma, sponsored by Dana-Farber Cancer Institute. Recruiting at 9 sites in United States. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.
Updated Nov 13, 20263 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Neuroblastoma by Dana-Farber Cancer Institute — 1 open to participants now, 2 under way, none of them phase 3. Neuroblastoma · Dana-Farber Cancer Institute.

Started
2025
the only one that year
No phase
2 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Neuroblastoma by Dana-Farber Cancer Institute, this one is the only one that started in 2025, is one of 2 with no phase, and was the 10th registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

1 of the 10 studies in Neuroblastoma by Dana-Farber Cancer Institute is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Neuroblastoma by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity [Pediatric RISE]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centered outcomes.

Participants will be randomized to receive one of the following for 6-months:

  • Usual supportive care alone or
  • Usual supportive care plus Pediatric RISE
Read the detailed description

This is a randomized Phase II trial evaluating the addition of the RISE supportive care equity intervention to usual supportive care for poverty-exposed children participants with newly diagnosed high-risk neuroblastoma. Participants will be randomized into one of two groups: Usual supportive care or Pediatric RISE plus usual supportive care. Randomization means a participant is placed into a study group by chance.

The research study procedures include screening for eligibility, in-person or virtual appointments, and surveys.

Participation in this research study is expected to last for about 6-months.

It is expected that about 84 participants will take part in this research study.

03

Conditions studied

  • Neuroblastoma
  • High-risk Neuroblastoma

Browse trials for

Keywords

  • Neuroblastoma
  • High-risk Neuroblastoma
04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient cohort: The randomized Phase II multi-center RISE intervention will be conducted among a population of poverty-exposed children with high-risk neuroblastoma. Poverty will be a priori defined as parent-reported low-income (\<200% Federal Poverty Level). Children receiving treatment for cancer at study sites will serve as the study cohort, with parents/guardians as survey informants and intervention recipients on behalf of their minor children given that parents (not children) typically manage household finances.

  • Patient newly diagnosed with high-risk neuroblastoma
  • Patient has established care at study site and initiated cancer-directed therapy
  • Patient has not yet initiated Induction Cycle 3
  • Patient aged 0-17 years at the time of consent
  • Parent/guardian screened positive for self-reported low-income (\<200% Federal Poverty) *
  • Family primary residence in MA, PA, IL, CA, WA, CT, GA, WI and OH
  • Both patients co-enrolled on ANBL2131 or those receiving standard of care therapy at their center are eligible to participate
  • Patients of all languages are eligible to participate

Exclusion criteria

Exclusion Criteria:

  • Foreign national family receiving care as an Embassy-pay patient.
  • Child or household member receiving SSI
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Arm 1: RISE Intervention + Usual Supportive Care

    Participants will be randomized in a 1:1 ratio and stratified according to treatment group and Household Material Hardship (HMH) severity score. Participant parents/guardians will complete: * Orientation visit in-person, by phone, or virtually with survey * Access to usual supportive oncology care comprised of social workers, resource specialists and/or psychosocial oncology teams * Meeting with a benefits counselor by phone or virtually and follow up meetings if needed * Fixed amount of cash assistance 2x monthly * 3 months survey * 6 month survey

    Behavioral: RISE Intervention

  • No intervention
    Arm 2: Usual Supportive Care

    Participants will be randomized in a 1:1 ratio and stratified according to treatment group and HMH severity score. Participant parents/guardians will complete: * Orientation visit in-person, by phone, or virtually with survey * Access to usual supportive oncology care comprised of social workers, resource specialists and/or psychosocial oncology teams * 3 month survey * 6 month survey

Interventions

  • BehavioralRISE Intervention

    Income-poverty targeted, supportive care intervention that includes direct cash transfers delivered by the Fund for Guaranteed Income, a non-profit organization, along with benefits counseling to discuss the risk of means-tested benefits loss or reduction. Funds will be dispersed to families via debit card or through personal banking, PayPal, or Venmo on a twice monthly basis for a total of twelve disbursements (6-months). Meetings with a benefits counselor will be conducted by the HIPAA-compliant video conference platform, Zoom.

    Also known as: Pediatric Resource Intervention to Support Equity

06

What researchers measure

Primary outcomes

  1. Household Material Hardship (HMH) Score Reduction Rate

    HMH score reduction rate is defined as the proportion of patients achieving at least 1 domain reduction in (food, housing, utility or transportation insecurity). HMH scores range from 0 to 4, with scores of 0 indicating no hardship (unexposed) and scores of 1-4 indicating the presence of hardship (exposed). Patients who are unexposed to HMH at baseline (HMH score of 0) are excluded from the analysis.

    Time frame: Baseline (T1) and 6-months (end-intervention; T3)

Secondary outcomes

  1. Pediatric-Modified Comprehensive Score for Financial Toxicity (COST)

    Financial toxicity will be assessed with the 12-item modified COST measure. Each item is rated on a 0-4 scale, yielding a total score range of 0-48, with higher scores indicating better financial well-being. The final COST score will be calculated per established methods. A change of approximately 5 points is considered a minimally important difference (MID), representing a clinically meaningful change in financial toxicity.

    Time frame: 3-months (end-of-induction; T2) and 6-months (end-intervention; T3)

  2. Parent Psychological Distress (Kessler-6) Score Change from Baseline to 6 Months

    Psychological distress will be assessed using the 6-item Kessler-6 scale. The scale includes 6 items scored from 0 ('none of the time') to 4 ('all of the time'), yielding a total score ranging from 0 to 24, with higher scores indicating greater psychological distress. A reduction in scores of approximately 2.8 points is considered a minimally important difference (MID), representing a clinically meaningful improvement in psychological distress.

    Time frame: Baseline (T1) and 6-months (end-intervention; T3)

  3. Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive Abilities Score Change from Baseline to 6 Months

    The PROMIS Applied Cognition-Abilities short form is an 8-item measure assessing subjective learning and memory, attention and concentration, executive function, and processing speed. Responses are scored on a scale of 1-5, and the total score is converted to a T-score with a mean of 50 and a standard deviation (SD) fixed at 10. Higher scores suggest better perceived cognitive function.

    Time frame: Baseline (T1) and 6-months (end-intervention; T3)

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Dr. Kira Bona. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Jun 2029, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Feb 18, 2025
StartActual
Apr 30, 2025
Primary completionEst.
Jun 1, 2029
CompletionEst.
Jun 1, 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 United States)
  • Children's Hospital Colorado · Aurora, United States
  • Columbia University Medical Center · New York, United States
  • Cincinnati Children's Hospital Medical Center · Cincinnati, United States
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    3 sites added
    Show 3 added (3 United States)
    • Children's Hospital Colorado · Aurora, United States
    • Columbia University Medical Center · New York, United States
    • Cincinnati Children's Hospital Medical Center · Cincinnati, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06831552
Responsible party
Kira Bona, MD, MPH (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Feb 18, 2025
Start date
Apr 30, 2025
Primary completion
Jun 1, 2029 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Kira Bona, MD, MPH
Contact
Kira_Bona@dfci.harvard.edu
617-632-4688
Kira Bona, MD, MPH
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion